Please ensure Javascript is enabled for purposes of website accessibility

FDA Evaluates 5 More COVID-19 Antibody Tests

By Brian Orelli, PhD – Jun 5, 2020 at 7:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Independent analysis shows some of the post-exposure tests work fairly well.

The U.S. Food and Drug Administration, together with the National Institutes of Health's National Cancer Institute, the Centers for Disease Control and Prevention, and the Biomedical Advanced Research and Development Authority, have been independently evaluating serology tests that detect the presence of antibodies against SARS-CoV-2, the novel coronavirus that causes COVID-19. The post-recovery tests will be especially helpful for people who think they had COVID-19 but weren't able to get a diagnostic test for the virus while they were infected.

Last month, the agencies released data on over a dozen antibody tests, and now they've followed up with data from five additional tests, including three that are no longer being sold in the U.S.

Gloved hand holding a vial marked positive for COVID-19

Image source: Getty Images.

One of the tests in the recent batch that still has an emergency use authorization, Healgen's COVID-19 IgG/IgM Rapid Test Cassette, scored quite high with a sensitivity -- the ability to detect a true positive case -- of 100% and a specificity -- the ability to detect a true negative -- of 97.5%. That's comparable to Abbott Labs' (ABT -1.56%) Architect SARS-CoV-2 IgG, which registered a sensitivity of 100% and a specificity of 99.6% in the previous round of testing.

The PerkinElmer (PKI -0.85%) EUROIMMUN SARS-CoV-2 ELISA (IgG) test wasn't quite as good, with a sensitivity of 90% and a specificity of 100%. While the results aren't competitive with the best tests, PerkinElmer's test can certainly find a place on the market, where demand outstrips supply. Bio-Rad Laboratories' (BIO -0.26%) Platelia SARS-CoV-2 Total Ab, for instance, has a sensitivity of 92.2% and a specificity of 99.6%.

The evaluations, which were run in April, also included three tests that are no longer on the market. Biomedomics and Phamatech voluntarily withdrew their tests, while Tianjin Beroni Biotechnology's test was removed from the market.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PerkinElmer, Inc. Stock Quote
PerkinElmer, Inc.
PKI
$120.33 (-0.85%) $-1.03
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$96.76 (-1.56%) $-1.53
Bio-Rad Laboratories, Inc. Stock Quote
Bio-Rad Laboratories, Inc.
BIO
$417.14 (-0.26%) $-1.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.